Lung Cancer Vitals for February 2017

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

We screened 685 studies on Lung Cancer this month. These are the most important.


NSCLC: post-RT cardiac events linked to heart dose

Source: J Clin Oncol



  • Clinically significant cardiac events that occur after high-dose thoracic radiation therapy in stage III NSCLC were associated with heart dose and cardiac risk and were observed relatively soon after treatment in a study of 127 patients.
  • The findings highlight the necessity of minimizing heart doses to patients with stage III NSCLC.

 

More details »  


Extensive SCLC: add-on bevacizumab boosts PFS, but not OS

Source: J Clin Oncol



  • Combining bevacizumab with standard platinum plus etoposide chemotherapy does not improve OS in extensive disease SCLC, but does significantly improve PFS, according to a multicenter phase 3 trial.
  • Treatment options for SCLC are limited, and these results highlight the need for further studies with novel and better antiangiogenic agents.

 

 More details » 

 


Other recent Vitals: